Abstract:Abstract Tumor genomes often harbor a complex spectrum of single nucleotide mutations, small indels, and large chromosome rearrangements that can perturb coding and non-coding regions of the genome in ways that remain poorly understood. The mutational processes responsible for the genesis of these events are also not static; instead, they continue to operate throughout disease evolution and further diversify the genetic and phenotypic landscape of cancer cells. Mounting evidence suggests that tumor genotype can be an important determinant of disease progression and therapy response, such as by modulating the sensitivity or resistance of cancer cells to mutant-specific drugs. These types of observations have motivated efforts to treat cancers with genome-informed therapies, highlighting the need to understand how different genetic variants precisely affect gene function and overall tumor phenotypes. Variant-function maps that provide a mechanistic understanding of the biology driven by cancer-associated mutations are needed to design these types of treatment strategies. Precision genome editing technologies like base and prime editing are uniquely suited to tackle this problem. Nevertheless, deploying these methods for systematic variant-function studies and disease modeling in vivo has not been straightforward due to lack of robust and scalable platforms capable of assessing editing efficiency and precision, particularly at endogenous loci. With this goal in mind, we previously developed and applied high-throughput base editing ‘sensor’ approaches that link endogenous genome editing outcomes with synthetic DNA-based readouts and cellular fitness measurements. Using these approaches, we showed that several uncharacterized mutant p53 alleles drive cancer cell proliferation and in vivo tumor development. Building upon this work, we recently developed new prime editing guide RNA design tools and sensor-based approaches that similarly couple quantitative editing outcomes to cellular fitness, allowing us to significantly expand the breadth of cancer-associated mutations that can be interrogated using these precision genome editing technologies. In this talk, I will describe ongoing work using base and prime editing sensor libraries to probe the biological impact of thousands of functionally-distinct genetic variants in diverse types of protein-coding genes and families to learn how these influence various cancer phenotypes. I will also discuss how the implementation of these modular technologies will allow researchers to functionally disentangle the impact of endogenous and exogenous mutational processes on functional selection and tumor evolution with close to single base pair resolution. This generalizable precision genome editing framework will facilitate the functional interrogation of genetic variants across diverse biological contexts, providing much needed insight into cancer variant-function relationships that could be leveraged to develop more precise cancer treatment paradigms, including synthetic lethal therapies that exploit tumor genotype. Citation Format: Francisco J. Sánchez-Rivera, Samuel I. Gould, Alexandra N. Wuest, Kexin Dong, Grace A. Johnson, Alvin Hsu, Varun K. Narendra, Ondine Atwa, Stuart S. Levine, David R. Liu. Functional studies of genetic variation using precision genome editing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA020.

Data from A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes

Functional genomic landscape of T-cell mediated cytotoxicity.

Supplemental Table 3 from A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Abstract 2500: Technical feasibility of CRISPR-based functional profiling for solid tumor precision medicine

A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets

Abstract IA020: Functional studies of genetic variation using precision genome editing

In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant.

Computational resources to define alleles and altered regulatory motifs at genomically edited candidate response elements

Supplemental Methods, Figures 1 - 12, Tables 1 - 2, 4 from A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes

Abstract 950: Functional characterization of atypical somatic variants in the Gundersen Precision Oncology Cohort

Highly parallel identification of essential genes in cancer cells

Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation

Abstract 4311: Using multiomics analysis to identify dysregulated transcription factors in non-small cell lung cancer (NSCLC) to drive the expression of a cancer-activated synthetic biomarker

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Abstract 2928: Solving the cancer mutation conundrum: A single cell, massively parallel approach for cancer mutation discovery, genome modelling and functional characterization

High-resolution characterization of gene function using single-cell CRISPR tiling screen

Functional genomic screens with death rate analyses reveal mechanisms of drug action